CCL2 and glioblastoma: We found that CCL2 was associated positively with the infiltration of some immune cells and the level of immune checkpoints in GBM tissue, therefore providing at least one mechanistic explanation for the predictive role of CCL2 in ICB therapy response in GBM patients.